Cargando…

Cardiac safety of afatinib: a review of data from clinical trials

BACKGROUND: Afatinib is an oral irreversible ErbB family blocker that targets epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and HER4 (ErbB4) and is approved for the first-line treatment of advanced non–small cell lung cancer (NSCLC) with certai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ewer, Michael S., Patel, Kalpesh, O’Brien, Dennis, Lorence, Robert M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837143/ https://www.ncbi.nlm.nih.gov/pubmed/33530147 http://dx.doi.org/10.1186/s40959-015-0006-7

Ejemplares similares

Cardiac Safety of Osimertinib: A Review of Data
por: Ewer, Michael S., et al.
Publicado: (2021)

Efficacy and Safety Results of the Afatinib Expanded Access Program
por: Kim, Edward S., et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
por: Wind, Sven, et al.
Publicado: (2016)

Cardiovascular adverse events in oncology trials: understanding and appreciating the differences between clinical trial data and real-world reports
por: Ewer, Michael S., et al.
Publicado: (2022)

Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients
por: Wang, Lei-Yun, et al.
Publicado: (2018)

Medication adjustment of afatinib and combination therapy with sitagliptin for alleviating afatinib-induced diarrhea in rats
por: Zhang, Li, et al.
Publicado: (2023)

Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data
por: Hopkins, Ashley M., et al.
Publicado: (2019)

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
por: Harvey, R Donald, et al.
Publicado: (2020)

“Liquid elbows” due to afatinib administration
por: Zarogoulidis, Paul, et al.
Publicado: (2017)

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
por: O’Brien, Mary E. R., et al.
Publicado: (2018)

Clinical and comparative utility of afatinib in non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2014)

Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations
por: Wang, Shouzheng, et al.
Publicado: (2019)

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
por: Schuler, M., et al.
Publicado: (2016)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023)

Afatinib in Non–Small Cell Lung Cancer
por: Wirth, Scott M.
Publicado: (2015)

Chinese Medicine Treatment for Afatinib-Induced Paronychia
por: Yang, Pei-Yuu, et al.
Publicado: (2017)

Afatinib use in recurrent epithelial ovarian carcinoma
por: Shepherd-Littlejohn, Amanda L., et al.
Publicado: (2019)

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
por: Schuler, Martin, et al.
Publicado: (2012)

Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials
por: Hopkins, Ashley M., et al.
Publicado: (2018)

Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC
por: Kulkarni, Amit A, et al.
Publicado: (2022)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019)

Toxic epidermal necrosis associated with afatinib: A case report and literature review
por: Yang, Wei, et al.
Publicado: (2023)

A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations
por: Song, Si-Yeon, et al.
Publicado: (2020)

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
por: Schnell, David, et al.
Publicado: (2014)

Afatinib in advanced NSCLC: a profile of its use
por: Deeks, Emma D., et al.
Publicado: (2018)

First reported case of afatinib‐associated toxic megacolon
por: Kwok, Wang Chun, et al.
Publicado: (2018)

Mechanisms of acquired resistance to afatinib clarified with liquid biopsy
por: Nakamura, Tomomi, et al.
Publicado: (2018)

Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program
por: Tu, Hai-Yan, et al.
Publicado: (2020)

Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial
por: Saran, Frank, et al.
Publicado: (2021)

The Efficacy and Safety of Afatinib in Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Meta-Analysis
por: Jin, Hui, et al.
Publicado: (2023)

A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations: Erratum
Publicado: (2022)

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
por: Miura, Satoru, et al.
Publicado: (2023)

Second-line afatinib administration in an elderly patient with squamous cell carcinoma
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2017)

Modeling Exposure‐Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib
por: Niebecker, Ronald, et al.
Publicado: (2019)

Afatinib for the treatment of metastatic non-small cell lung cancer
por: Joshi, Monika, et al.
Publicado: (2015)

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
por: Nelson, Valerie, et al.
Publicado: (2013)

Afatinib-Induced Acute Fatal Pneumonitis in Metastatic Lung Adenocarcinoma
por: Yoo, Sang Hoon, et al.
Publicado: (2016)

Role of afatinib in the treatment of advanced lung squamous cell carcinoma
por: Vavalà, Tiziana
Publicado: (2017)

Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer
por: Tamura, Shuzo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3tordnv921rkkaalp7t6qv6d5s